natgillin/translations-raw huggingface dataset:
Pakningstørrelser: 14 , 28 , 30 , 56 , 84 , 90 , 98 eller 100 tabletter.
Pack sizes: 14, 28, 30, 56, 84, 90, 98 or 100 tablets.
Palackého třída 163a 612 00 Brno
Velika Britanija.
Palifermin (60 mikrogram/kg/dag)
Palifermin (60 micrograms/kg/day)
Palifermin virker på samme måde som keratinocyt vækstfaktor (KGF), der produceres naturligt af kroppen i små mængder.
Palifermin works in the same way as keratinocyte growth factor (KGF) which is made naturally by your body in small amounts.
Palifermin virker på samme måde som keratinocyt vækstfaktor (KGF), der produceres naturligt af kroppen i små mængder.
The replacement palifermin acts in the same way as naturally produced KGF.
Paliperidon
Paliperidone
Paliperidon binder kraftigt til serotonerge 5-HT2- og dopaminerge D2-receptorer.
Paliperidone binds strongly to serotonergic 5-HT2- and dopaminergic D2-receptors.
Paliperidon binder kraftigt til serotonerge 5-HT2-receptorer og dopaminerge D2- receptorer.
Paliperidone binds strongly to serotonergic 5-HT2- and dopaminergic D2-receptors.
Paliperidon blokerer også alfa-1-adrenerge receptorer og blokerer i mindre grad H1- histaminerge og alfa-2-adrenerge receptorer.
Paliperidone also blocks alfa1-adrenergic receptors and blocks, to a lesser extent, H1-histaminergic and alfa2-adrenergic receptors.
Paliperidon er den aktive metabolit af risperidon.
There is no specific antidote to paliperidone.
Paliperidon er risperidons aktive metabolit.
Paliperidone is the active metabolite of risperidone.
Paliperidon forventes ikke at forårsage klinisk vigtige farmakokinetiske interaktioner med lægemidler, som metaboliseres af cytokrom P450-isozymer.
Paliperidone is not expected to cause clinically important pharmacokinetic interactions with medicines that are metabolised by cytochrome P-450 isozymes.
Paliperidon må ikke anvendes til patienter med kreatininclearance under 10 ml/min.
Paliperidone should not be used in patients with creatinine clearance below 10 ml/min.
Paliperidon skal anvendes med forsigtighed til patienter med mulige prolaktin- afhængige tumorer.
Paliperidone should be used with caution in patients with possible prolactin-dependent tumours.
Paliperidon udskilles i human mælk i så stor en mængde, at en påvirkning af det ammede barn er sandsynlig, hvis terapeutiske doser administreres til ammende kvinder.
Paliperidone is excreted in the breast milk to such an extent that effects on the breastfed infant are likely if therapeutic doses are administered to breastfeeding women.
Paliperidon virker hovedsagelig på receptorerne for neurotransmitterne dopamin og serotonin (5-hydroxytryptamin).
Paliperidone acts mainly by blocking the receptors for the neurotransmitters dopamine and 5- hydroxytryptamine (also called serotonin).
Paliperidonpalmitat er palmitatester-prodrug af paliperidon.
Paliperidone palmitate is the palmitate ester prodrug of paliperidone.
Paliperidons absolutte orale biotilgængelighed efter administration af INVEGA er 28 % (90 % CI af 23 %-33 %).
The absolute oral bioavailability of paliperidone following INVEGA administration is 28% (90% CI of 23%-33%).
Paliperidons gennemsnitlige terminale eliminationshalveringstid var 24, 40 og 51 timer hos personer med henholdsvis let, moderat og svært nedsat nyrefunktion sammenlignet med 23 timer hos personer med normal nyrefunktion (CrCl ≥ 80 ml/min).
The mean terminal elimination half-life of paliperidone was 24, 40, and 51 hours in subjects with mild, moderate, and severe renal impairment, respectively, compared with 23 hours in subjects with normal renal function (CrCl ≥ 80 ml/min).
Paliperidons plasmaproteinbinding er 74 %.
The plasma protein binding of paliperidone is 74%.
Palivizumab administreresintramuskulært, helst anterolateralt i låret.
Palivizumab is administered intramuscularly, preferably in the anterolateral aspect of the thigh.
Palivizumab binder til et specifik område på det ekstracellulære domæne på det modne RSV-F- protein, som benævnes antigen-site II eller antigen-site A, der omfatter aminosyre 262 til 275.
Palivizumab binds a highly conserved region on the extracellular domain of mature RSV F protein, referred to as antigenic site II or A antigenic site, which encompasses amino acids 262 to 275.
Palivizumab er et humaniseret IgG1K monoklonalt antistof rettet mod en epitop på det A antigene site på fusionsproteinet af respiratorisk syncytial-virus (RSV).
Palivizumab is a humanised IgG1 monoclonal antibody directed to an epitope in the A antigenic site of the fusion protein of respiratory syncytial virus (RSV).
Palivizumab er udformet, så det bindes til et protein, der kaldes fusionsprotein A, på overfladen af RSV.
Palivizumab has been designed to attach to a protein called ‘fusion protein A’ on the surface of RSV.
Palivizumab frysetørret formulering
Lyophilised formulation of palivizumab
Palivizumab frysetørret formulering:
Lyophilised formulation of palivizumab
Palivizumab indgives i en dosis på 15 mg/kg en gang om måneden intramuskulært, helst anterolateralt i låret.
Palivizumab is administered once a month intramuscularly, preferably in the anterolateral aspect of the thigh.
Palivizumab opløsning indeholder ikke konserveringsmiddel og skal indgives inden for 3 timer efter tilberedningen.
Palivizumab solution does not contain a preservative and should be administered within 3 hours of preparation.
Palivizumab påvirker ikke analyser baseret på revers transkriptase-polymerase- kæde-reaktion.
Palivizumab does not interfere with reverse transcriptase polymerase chain reaction-based assays.
Palivizumab volumen ( i ml), der skal administreres med intervaller på 1 måned = [patientens vægt i kg] multipliceret med 0,15.
The volume (expressed in mL) of // Palivizumab // to be administered at one-monthly intervals = [patient weight in kg] multiplied by 0.15
Palivizumab volumen ( i ml), der skal administreres med intervaller på 1 måned = [patientens vægt i kg] multipliceret med 0,15.
The volume (expressed in ml) of // Palivizumab // to be administered at one-monthly intervals = [patient weight in kg] multiplied by 0.15.
Palivizumab-serumkoncentrationer på cirka 30 g/ml er vist at medføre en 99% reduktion i pulmonal RSV-replikation i cotton- rat-modellen.
Palivizumab serum concentrations of approximately 30 g/ml have been shown to produce a 99% reduction in pulmonary RSV replication in the cotton rat model.
Palivizumabopløsning bør ikke blandes med andre lægemidler eller opløsningsmidler end vand til injektionsvæsker.
Palivizumab should not be mixed with any medicinal products or diluents other than water for injections.
Palladia 10 mg filmovertrukne tabletter til hund Palladia 15 mg filmovertrukne tabletter til hund Palladia 50 mg filmovertrukne tabletter til hund
Palladia 10 mg film-coated tablets for Dogs Palladia 15 mg film-coated tablets for Dogs Palladia 50 mg film-coated tablets for Dogs
Palladia 10 mg tabletter til hund. (pictogram) Palladia 15 mg tabletter til hund.
Palladia 10 mg tablets for dogs.(pictogram) Palladia 15 mg tablets for dogs.
Palladia 50 mg filmovertrukne tabletter til hund. toceranib
Palladia 50 mg film-coated tablets for dogs. toceranib
Palladia 50 mg filmovertrukne tabletter til hund. toceranib
Palladia 50 mg film-coated tablets for dogs. toceranib.
Palladia 50 mg tabletter til hund. toceranib
Palladia 50 mg tablets for dogs. toceranib
Palladia-tabletterne bør gives til din hund umiddelbart efter, de er taget ud af blisterpakningen og bør ikke efterlades, hvor de kan håndteres/sluges af børn.
Palladia tablets should be given to your dog immediately after they are removed from the blister and should not be left around where they could be handled/swallowed by children.
Palladias sikkerhed er vurderet hos mastcelletumor-bærende hunde med følgende værdier:
The safety of Palladia was evaluated in mast cell tumour-bearing dogs with the following:
Pallagi út 13 Ungarn
Pallagi út 13 Hungary
Pallagi út 13 Ungarn
Pallagi út 13, Hungary
Pallagi út 13, 4042 Debrecen, Ungarn
4042 Debrecen, Hungary
Pallagi út 13, Ungarn
Pallagi út 13, Hungary
Pallini 15351 Attiki Grækenland
15351 Pallini, Attiki Greece
Pallini 15351 Attiki Grækenland
Pallini 15351
Pallini 15351 Attiki Grækenland
Pallini 15351 Attiki Greece
Pallini 15351 Attiki Grækenland
Pallini 15351, Attiki Greece
Pallini 15351 Attiki Grækenland
Pallini Attiki, 15351 Greece
Pallini 15351 Attiki, Grækenland
Pallini 15351 Attiki, Greece
Pallini 15351, Attiki, Grækenland Tel.: +30 210 66 04 300
Tel.: +30 210 66 04 300
Pallini Attiki Grækenland
15351 Pallini Attiki Greece‌‌
Palmar- plantar erytro- dysæsthesi syndrom
Palmar-plantar erythro- dysaesthesia syndrome
Palmar- plantar erytrodysæst esi syndrom
Palmar-plantar erythro- dysaesthesia syndrome
Palmar-plantar erythrodysæstesi syndrom**
Palmar-plantar
Palmar-plantar erytrodysæstes i syndrom**
Palmar-plantar erythrodysaesthesi a syndrome
Palmar-plantar erytrodysæstesi (udslæt og følelsesløshed på håndflader og fodsåler) er også meget almindelig, når Tyverb tages sammen med capecitabin.
Palmar- plantar erythrodysaesthesia (rash and numbness on the palms and soles) is also very common when Tyverb is taken with capecitabine.
Palmar-plantar erytrodysæstesi syndrom**
Palmar-plantar
Palmar-plantar erytrodysæstesi syndrom**
Palmar-plantar erythro- dysaesthesia syndrome
Palmar-plantar erytrodysæstesi syndrom, udslæt, hyperpigmenterin g af hud, tør hud, pruritus, alopeci
Palmar-plantar erythrodysaesthesia syndrome, rash, skin hyperpigmentation, dry skin, pruritus, alopecia,
Palmar-plantar erytrodysæstesisyn drom
ite conditions
Palmar-plantar erytrodysæstesisyndrom, alopeci
Palmar-plantar erythrodysaesthiesia syndrome, alopecia
Palmo-plantar erytrodysæstesi (hånd-og fodsyndrom)
Palmar-plantar erythrodysaesthesia (hand-foot syndrome)
Palmoplantar erytrodysæestesi (PPE) (hånd-fod-syndrom)
Palmar-plantar erythrodysaesthesia syndrome
Palmoplantar erytrodysæstesi
Palmar–Plantar erythrodysesthesia
palmoplantar erytrodysæstesi (PPE)
palmar-plantar erythrodysesthesia (PPE)
Palmoplantar erytrodysæstesi (PPE) (hånd-fod-syndrom) var også almindeligt (> 25 %), når lapatinib blev administreret i kombination med capecitabin.
Palmar-plantar erythrodysesthesia [PPE] was also common (>25%) when lapatinib was administered in combination with capecitabine.
Palmoplantar erytrodysæstesi syndrom*, lichenoid keratosis*, lichen planus*, toksisk epidermal nekrolyse*, medikamentelt udslæt med eosinofili og systemiske symptomer (DRESS)*
Palmoplantar erythrodysesthesia syndrome*, lichenoid keratosis*, lichen planus*, toxic epidermal necrolysis*, drug rash with eosinophilia and systemic symptoms (DRESS)
Palmoplantar erytrodysæstesi- syndrom
Palmar-plantar erthyrodysaesthesia syndrome
Palmoplantar erytrodysæstesi- syndrom
Palmar-plantar erythrodysaesthesia syndrome
Palmoplantar erytrodysæstesi- syndrom, panniculit (inklusive erythema nodosum), keratosis pilaris
Palmar-plantar erythrodysaesthesia syndrome, panniculitis (including erythema nodosum), keratosis pilaris
palmoplantar erytrodysæstesi- syndrom, ændringer i hårfarve, udslæt, tør hud, alopeci, erytem
palmar-plantar erythrodysaesthesia syndrome, hair colour changes, rash, dry skin, alopecia, erythema
Palmoplantar erytrodysæstesi-syndrom
Palmar –plantar erythrodysaesthesia syndrome
Palmoplantar erytrodysæstesi-syndrom, udslæt, tør hud
palmar-plantar erythrodysaesthesia syndrome, rash, dry skin
palmoplantar erytrodysæstesisyndrom (11,0 % versus 4,3 % alle grader; 2,8 % versus 0,5 % grad 3-4), hyperpigmentering af huden (8,2 % versus 2,8 % alle grader; 0 versus 0 grad 3-4).
Erythrodysaesthesia syndrome (11.0% versus 4.3% all grades; 2.8% versus 0.5% Grades 3-4), and skin hyperpigmentation (8.2% versus 2.8% all grades; 0 versus 0 Grades 3-4).
Palmoplantar erytrodysæstesisyndromc Udslæt
Palmar-plantar erythrodysaesthesia syndromec
Palmoplantar syndrom (dvs. rødme, hudafskalning eller blister på hænder og fødder)
Palmar plantar syndrome (i.e. redness, skin peeling or blisters on hands and feet)
Palonosetron 0,5 mg
Palonosetron 0.5 mg
Palonosetron 250 mikrogram
Palonosetron 250 micrograms
Palonosetron Accord 250 mikrogram injektionsvæske, opløsning palonosetron
Palonosetron Accord 250 micrograms solution for injection palonosetron
Palonosetron Accord 250 mikrogram injektionsvæske, opløsning palonosetron (som hydrochlorid)
Palonosetron Accord 250 micrograms solution for injection palonosetron (as hydrochloride)
Palonosetron Accord 250 mikrogram injektionsvæske, opløsning.
Palonosetron Accord 250 micrograms solution for injection
Palonosetron Accord anvendes til forebyggelse af kvalme og opkastning i forbindelse med kemoterapi mod kræft hos voksne, unge og børn, som er over en måned gamle.
Palonosetron Accord is used for the prevention of nausea and vomiting associated with cancer chemotherapy in adults, adolescents and children over one month of age.
Palonosetron Accord bør ikke anvendes til at forebygge og behandle kvalme og opkastning i dagene efter kemoterapi, medmindre det sker i forbindelse med anden indgift af kemoterapi.
Palonosetron Accord should not be used to prevent or treat nausea and vomiting in the days following chemotherapy if not associated with another chemotherapy administration.
Palonosetron Accord bør kun anvendes før indgift af kemoterapi.
Palonosetron Accord should be used only before chemotherapy administration.
Palonosetron Accord er hos voksne indiceret til:
Palonosetron Accord is indicated in adults for:
Palonosetron Accord hører til en gruppe lægemidler, der kaldes serotonin (5HT3)- antagonister.
Palonosetron Accord belongs to a group of medicines known as serotonin (5HT3) antagonists.
Palonosetron Accord indeholder mindre end 1 mmol (23 mg) natrium pr. hætteglas, dvs. den er i det væsentlige natriumfri.
This medicine contains less than 1 mmol sodium (23 mg) per vial, i.e. essentially ‘sodium- free’.
Palonosetron Accord kan fremkalde svimmelhed eller træthed.
Palonosetron accord may cause dizziness or tiredness.
Palonosetron Accord skal injiceres over 30 sekunder.
Palonosetron Accord should be injected over 30 seconds.
Palonosetron Accord vil blive givet som en langsom infusion i en blodåre.
Palonosetron accord will be given as a slow infusion into a vein.
Palonosetron Accord-injektionsvæske, opløsning, er en klar og farveløs opløsning, der leveres i et 6 ml hætteglas lukket med en chlorbutylgummiprop og forseglet med en ”flip-off”-aluminiumforsegling.
Palonosetron Accord solution for injection is a clear, colourless solution supplied in a 6 ml glass vial, closed with chlorobutyl rubber stopper and sealed with a flip-off aluminium seal.
Palonosetron er indgivet sikkert sammen med kortikosteroider.
Palonosetron has been administered safely with corticosteroids.
Palonosetron Hospira er et "generisk lægemiddel".
Palonosetron Hospira is a ‘generic medicine’.
Palonosetron hæmmer ikke og inducerer ikke CYP- isoenzymer i klinisk relevante koncentrationer.
Palonosetron does not inhibit or induce cytochrome P450 isoenzymes at clinically relevant concentrations.
Palpation af abdomen bør være tilstrækkeligt til at afgøre abnorm forstørrelse af milten.
Abdominal palpation should be sufficient to detect abnormal increases in splenic volume.
Palpitation
angioedema
Palpitation Atrieflimren
Palpitation Atrial fibrillation
Palpitation, sinus takykardi
Palpitation, sinus tachycardia
Palpitation, tachycardi
Palpitation, tachycardia
palpitationer
abnormal, palpitations
Palpitationer
common
Palpitationer
Nausea, vomiting
Palpitationer
palpitations,
Palpitationer (herunder takykardi)
Palpitations (including tachycardia)
Palpitationer (NB,N,B)a, ændring i elektrokardiogram (N)
Palpitations (NB,N,B)a, Electrocardiogram change (N)
Palpitationer Almindelig
Palpitations Common
Palpitationer Ikke almindelig
Palpitations Uncommon
Palpitationer, AV-blok af første grad, ekstrasystoler, takykardi, arytmi
Palpitations, AV block first degree, Extrasystoles, Tachycardia, Arrhythmia
Palpitationer, bradykardi, sinusbradykardi
Palpitations, bradycardia, sinus bradycardia
Palpitationer, dyspnø
Palpitations, dyspnoea
Palpitationer, sinusbradykardi, ventrikulære ekstrasystoler
palpitations, sinus bradycardia, ventricular extrasystoles
Palpitationer, takykardi, arytmi, atrieflimren, kongestiv hjerteinsufficiens
palpitations, tachycardia, arrhythmia, atrial fibrillation, cardiac failure congestive
Palpitationer1
Palpitations1
Palpitationer1,4
Palpitations1,4
Palpitationer2
Palpitations2
palpitationer2,3, takykardi3, øget hjerterytme3, brystsmerter2, ødem2
palpitations2,3, tachycardia3, increased heart rate3, chest pain2, oedema2
Palpitationere, atriefibrillatione
Palpitationse, atrial
Palpitationere, atriefibrillatione, supraventrikulæ r takykardie
fibrillatione, supraventricular tachycardiae
Pamidro- nat
Pamidronate
Pamidro- nat 90 mg
Pamidronate 90 mg
Pamidronat 90 mg (N = 99)
Pamidronate 90 mg (N=99)
Panacur AquaSol 200 mg/ml suspension til brug i drikkevand til svin og kyllinger
Panacur AquaSol 200 mg/ml suspension for use in drinking water for pigs and chickens Fenbendazole
Panacur AquaSol 200 mg/ml suspension til brug i drikkevand til svin og kyllinger Fenbendazol
Panacur AquaSol 200 mg/ml suspension for use in drinking water for pigs and chickens Fenbendazole
Panacur AquaSol 200 mg/ml, suspension til brug i drikkevand, til svin og kyllinger
Panacur AquaSol 200 mg/ml suspension for use in drinking water for pigs and chickens
Panacur AquaSol anvendes også til behandling af to typer rundormsinfektioner i kyllingers tarme:
Panacur AquaSol is also used for the treatment of two types of roundworm infections in the gut of chickens:
Panacur AquaSol er et lægemiddel, der indeholder det aktive stof fenbendazol.
Panacur AquaSol is a medicine that contains the active substance fenbendazole.
Panacur AquaSol må ikke udledes i vandløb, da dette kan være farligt for fisk og andre organismer i vandet.
Panacur Aquasol should not enter water courses as this may be dangerous for fish and other aquatic organisms.
Panacur AquaSol må ikke udledes i vandløb, da dette kan være farligt for fisk og andre organismer i vandet.
The veterinary medicinal product should not be allowed to enter surface waters as it has harmful effects on aquatic organisms.
Pancreas-insuffiens
Pancreatic insufficiency
Pancreascancer (samtidig administration af Tarceva og gemcitabin i studie PA.3):
Pancreatic cancer (Tarceva administered concurrently with gemcitabine in study PA.3):
Pancreascancer (samtidig administration af Tarceva og gemcitabin):
Pancreatic cancer (Tarceva administered concurrently with gemcitabine):
Pancreatitis
Rhabdomyolysis
Pancreatitis
Very Rare
Pancreatitis er blevet rapporteret som en ikke almindelig bivirkning.
Pancreatitis has been reported as an uncommon side effect.
Pancreatitis er rapporteret, men kausal sammenhæng med abacavir er usikker.
Pancreatitis has been reported, but a causal relationship to abacavir treatment is uncertain.
Pancreatitis i anamnesen eller kendte eller mistanke om strukturelle sygdomme i pancreas, herunder obstruktion af ductus pancreaticus.
A history of pancreatitis; or known or suspected structural diseases of the pancreas, including pancreatic duct obstruction.
pancreatitis i forbindelse
pancreatitis in the
Pancreatitis kan være en alvorlig, eventuelt livstruende tilstand.
Pancreatitis can be a serious, potentially life­threatening medical condition.
Pancreatitis Tarmobstruktion
Pancreatitis Intestinal obstruction
Pancreatitis,
Rare (1/10,000,
pancreatitis, colitis (inklusive ulcerøs eller lymfocytisk colitis), stomatitis
Gastrointestinal and retroperitoneal haemorrhage with fatal outcome, pancreatitis, colitis (including ulcerative or lymphocytic colitis), stomatitis
pancreatitis, forhøjet blodamylase, gastroesofageal reflukssygdom, stomatitis, dyspepsi, abdominal distension, abdominale gener, mundtørhed
pancreatitis, blood amylase increased, gastrooesophageal reflux disease, stomatitis, dyspepsia, abdominal distension, abdominal discomfort, dry mouth
Pancreatitis, iskæmisk colitis, ulcerativ colitis,
Pancreatitis, ischaemic colitis, ulcerative colitis, gingival
Pancreatitis, iskæmisk colitis, ulcerativ colitis, blødning af
Pancreatitis, ischaemic colitis, ulcerative colitis, gingival
pancreatitis, opsvulmet tunge,
pancreatitis, swollen tongue, faecal
pancreatitis, tarmobstruktione, ileus, opsvulmet tunge, fækalinkontinens, fækalom, dysfagi, cheilitise
pancreatitis, intestinal obstructione, ileus, swollen tongue, faecal incontinence, faecaloma, dysphagia, cheilitise
pancytopeni
pancytopaenia
Pancytopeni Granulocytopeni Monocytopeni Erytropeni Leukocytose
Pancytopenia Granulocytopenia Monocytopenia Erythropenia Leukocytosis
pancytopeni trombocytopeni, eosinofili, hypoalbuminæmi
pancytopenia, thrombocytopenia, eosinophilia, hypoalbuminaemia
Pancytopeni – en kombination af lavt antal hvide blodlegemer, røde blodlegemer og blodplader.
Pancytopenia- combined low counts of white cells, red cells and platelets
Pancytopeni – en kombination af lavt antal hvide blodlegemer, røde blodlegemer og blodplader.
Pancytopenia-combined low counts of white cells, red cells and platelets
pancytopeni*
pancytopaenia
Pancytopeni*
Pancytopenia
Pancytopeni*
Uncommon
Pancytopeni*, Agranulocytose*, Hæmolytisk anæmi*
Pancytopenia*, Agranulocytosis*, Haemolytic anaemia
pancytopeni*, knoglemarvsvigt
pancytopenia*, bone marrow failure
pancytopeni,
pancytopenia,
Pancytopeni, anæmi (grad 3 - 4), leukopeni
Pancytopenia, anaemia (Grade 3 – 4), leukopenia
pancytopeni, febril neutropeni, nedsat leukocyttal
pancytopenia, febrile neutropenia, white blood cell count decreased
Pancytopeni, forlænget protrombintid, øget INR (International Normalised Ratio), hypoprotrombinæmi, forkortet protrombintid, granulocytose, leukocytose, eosinofili, lymfocytose, reduceret monocyttal, øget monocyttal, , trombocytæmi
Pancytopenia, prothrombin time prolonged, international normalised ratio increased, hypoprothrombinaemia, prothrombin time shortened, granulocytosis, leukocytosis, eosinophilia, lymphocytosis, monocyte count decreased, monocyte count increased, thrombocythaemia
Pancytopeni, granulocytopeni
Pancytopenia, granulocytopenia
Pancytopeni, neutropeni, agranulocyto se
Pancytopenia, neutropenia, agranulocytosis
Pancytopeni, neutropeni, agranulocytose
Pancytopenia,, neutropenia, agranulocytosis
Pancytopeni, neutropeni, agranulocytose
Pancytopenia,neutropenia, agranulocytosis
pancytopeni, splenomegali, erytrocytose, morfologiske forandringer i de hvide blodlegemer
pancytopaenia, splenomegaly, erythrocytosis, white blood cell morphology abnormal
pancytopeni, trombocytopeni
pancytopenia, thrombocytopenia
pancytopeni, trombocytopeni2, leukopeni, anæmi
pancytopenia, thrombocytopenia2, leukopenia, anaemia
Pancytopeni1, trombocytopeni1, forværret anæmi1, neutropeni1
Pancytopenia1, thrombocytopenia1, anaemia aggravated1, neutropenia1
pandehulebetændelse
inflammation of the sinuses
Pandemic Influenza Vaccine H5N1 Baxter AG er blevet godkendt under ‘særlige omstændigheder’.
Pandemic Influenza Vaccine H5N1 Baxter AG has been authorised under ‘Exceptional Circumstances’.
Pandemic Influenza Vaccine H5N1 Baxter AG er en vaccine til forebyggelse af ‘pandemisk’ influenza.
Pandemic Influenza Vaccine H5N1 Baxter AG is a vaccine to prevent ‘pandemic’ flu.
Pandemic Influenza Vaccine H5N1 Baxter AG er en ‘mockup’-vaccine.
Pandemic Influenza Vaccine H5N1 Baxter AG is a ‘mock-up’ vaccine.
PANDEMIC INFLUENZA VACCINE H5N1 BAXTER er godkendt under ‘særlige omstændigheder’.
PANDEMIC INFLUENZA VACCINE H5N1 BAXTER has been authorised under ‘exceptional circumstances’.
PANDEMIC INFLUENZA VACCINE H5N1 BAXTER er godkendt under ”særlige omstændigheder”.
PANDEMIC INFLUENZA VACCINE H5N1 BAXTER has been authorised under “exceptional circumstances”.
PANDEMIC INFLUENZA VACCINE H5N1 BAXTER indeholder:
What PANDEMIC INFLUENZA VACCINE H5N1 BAXTER contains
PANDEMIC INFLUENZA VACCINE H5N1 BAXTER injektionsvæske, suspension Pandemisk influenzavaccine (H5N1) (hel virion, inaktiveret, fremstillet i cellekultur)
PANDEMIC INFLUENZA VACCINE H5N1 BAXTER, suspension for injection Pandemic influenza vaccine (H5N1) (whole virion, inactivated, prepared in cell culture)